Saccharomyces Boulardii DBVPG 6763

Overview

Saccharomyces boulardii DBVPG 6763 is a specific strain of the probiotic yeast Saccharomyces cerevisiae variant boulardii, recognized for its gastrointestinal supportive effects. Unlike bacterial probiotics, it is a non-pathogenic, acid-resistant, temperature-tolerant yeast that survives stomach acid, bile salts, and antibiotics, making it ideal for gut health support.¹² Primarily used to prevent and treat diarrhea, including antibiotic-associated and Clostridioides difficile infections, it also aids in balancing gut microbiota, reducing inflammation, and enhancing immune function.⁶ Discovered in the 1920s from lychee fruit, S. boulardii has been studied extensively since the 1960s for digestive disorders, with DBVPG 6763 showing promise in reducing low-grade inflammation and adiposity in obese individuals.³⁴

Forms and Variations

Saccharomyces boulardii DBVPG 6763 is commonly available in gastro-resistant capsules to protect it from stomach acid, ensuring delivery to the intestines. Typical formulations provide 5.0 × 10⁹ CFU per capsule, often combined with antioxidants like superoxide dismutase (SOD) for enhanced anti-inflammatory effects.³ Other variations include powders, lozenges, and higher-dose capsules up to 9 billion CFU, designed for non-colonizing, transient use.⁵ Strain-specific products like DBVPG 6763 are chosen for their researched efficacy in obesity-related inflammation and gut barrier support, differing from general S. boulardii strains (e.g., CNCM I-745) by unique genetic profiles and clinical outcomes.¹ Gastro-resistant forms are preferred for better viability and targeted action in the colon.²

Dosage and Administration

Recommended dosages for Saccharomyces boulardii DBVPG 6763 include 5.0 × 10⁹ CFU twice daily (total 10 billion CFU/day), taken with meals for 60 days in clinical studies on inflammation and obesity.³ General adult doses range from 250-500 mg (5-10 billion CFU) per day, divided into 1-2 administrations, while children may use lower doses for diarrhea prevention.⁶ Best practices involve taking it separately from antifungals, with food to enhance tolerance, and continuing during antibiotic therapy to prevent diarrhea. It is transient, clearing the body post-use without colonization.²⁵ Consult a healthcare provider for personalized dosing, especially in vulnerable groups.

Scientific Research and Mechanism of Action

Key studies on DBVPG 6763, combined with SOD, over 60 days in obese adults (BMI 30-35 kg/m²) showed reductions in inflammatory markers like CRP, TNF-α, IL-1β, and IL-6, alongside trends in lowering TMAO and improving body composition via DXA scans.³ It works by adhering to pathogens (e.g., C. difficile, E. coli, Salmonella), neutralizing toxins, and inhibiting their adhesion to intestinal cells. The yeast secretes factors that cleave pathogen virulence factors, boost secretory IgA, short-chain fatty acids, and enzymes for nutrient absorption.¹² Anti-inflammatory effects involve blocking NF-κB and MAP kinase pathways, reducing IL-8 and chloride secretion, restoring glutathione, and tightening intestinal barriers.¹ Research is promising but ongoing, with strain-specific data limited; broader S. boulardii evidence supports diarrhea prevention.⁶ Genetic mutations like G1278A in PGM2 enhance its 37°C growth advantage.¹

Benefits and Potential Uses

Proven benefits include preventing antibiotic-associated diarrhea and C. difficile recurrence in adults and children, supported by clinical evidence.⁶ DBVPG 6763 reduces low-grade inflammation, potentially aiding obesity management by lowering cytokines and TMAO.³ It supports gut barrier function, modulates immunity via IgA and anti-inflammatory cytokines, and nourishes colon cells with short-chain fatty acids.²⁴ Potential uses encompass IBS symptom relief (pain, bloating, bowel irregularity), ulcerative colitis/Crohn’s remission maintenance, intestinal infections (Salmonella, E. coli), and immune enhancement. It improves nutrient/mineral absorption and healthy inflammatory responses during digestive discomfort.¹⁴ Research indicates benefits for rotaviral diarrhea and H. pylori-related issues, though more strain-specific trials are needed.⁶

Side Effects and Risks

Common side effects are rare and mild, including gas, bloating, or constipation, typically resolving quickly.⁶ Risks are low as it is non-colonizing and transient, but fungemia (yeast in bloodstream) has occurred in immunocompromised individuals, ICU patients, or those with central venous catheters.⁶ Contraindications include severe immunosuppression or yeast allergies. Use caution in premature infants or critically ill patients due to rare systemic infections. Healthy individuals tolerate it well at clinical doses.²

Interactions and Precautions

S. boulardii resists antibiotics, allowing co-administration to prevent diarrhea, but avoid antifungals like fluconazole which may reduce efficacy.¹ No significant drug interactions reported, though it may enhance probiotic effects or alter gut microbiota balance with other supplements.² Precautions for pregnant/lactating women, children, and elderly: use under medical supervision due to limited strain-specific data. Avoid in short bowel syndrome or post-gastrointestinal surgery without advice. Discontinue before antifungal therapy or if infection suspected; monitor in ICU settings.⁶

Impact on Biomarkers

DBVPG 6763 supplementation decreases inflammatory biomarkers like CRP, TNF-α, IL-1β, IL-6, and trends lower TMAO levels, indicating reduced systemic inflammation.³ It may improve pro/antioxidant ratios via SOD synergy, lower HOMA-IR, glucose, insulin, and lipid profiles in obesity. Enhances secretory IgA and short-chain fatty acids, supporting gut health metrics; potential body composition shifts via reduced adiposity.³

Overdose and Toxicity

No established toxicity from over-supplementation; it is generally safe with no upper intake level defined, as excess is excreted.⁶ High doses may cause transient GI upset like bloating. Rare fungemia risks increase in vulnerable groups, with symptoms including fever and chills. Safe clinical doses up to 10 billion CFU/day for 60 days showed no adverse effects; seek immediate care for infection signs in at-risk patients.³⁵

Disclaimer

The information provided in this document is for educational purposes only and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.